BTK and mantle cell lymphoma: Given the practice-changing success of BTK inhibitors in treating R/R MCL, it was therefore of interest to establish a BTK inhibitor with efficacy in MCL following the treatment failure of ibrutinib, acalabrutinib, or zanubrutinib, all of which bind the same cysteine residue on BTK.